TRACON Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update

SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age‐related macular degeneration and fibrotic diseases, today announced financial results for the first quarter ended March 31, 2017.